A human monoclonal antibody potently pan-neutralizes SARS-CoV-2 VOCs by targeting RBD invariant sites

Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). The neutralizing monoclonal antibodies (mAbs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and treat COVID-19. However, SARS-CoV-2 variants of concern (VOCs) profoundly reduced the efficacies of most of mAbs and vaccines approved for clinical use. Herein, we demonstrated mAb 35B5 efficiently neutralizes both wild-type (WT) SARS-CoV-2 and VOCs, including B.1.617.2 (delta) variant, in vitro and in vivo. Cryo-electron microscopy (cryo-EM) revealed that 35B5 neutralizes SARS-CoV-2 by targeting a unique epitope that avoids the prevailing mutation sites on RBD identified in circulating VOCs, providing the molecular basis for its pan-neutralizing efficacy. The 35B5-binding epitope could also be exploited for the rational design of a universal SARS-CoV-2 vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (10790)
- Bioengineering (8039)
- Bioinformatics (27280)
- Biophysics (13970)
- Cancer Biology (11119)
- Cell Biology (16047)
- Clinical Trials (138)
- Developmental Biology (8777)
- Ecology (13276)
- Epidemiology (2067)
- Evolutionary Biology (17353)
- Genetics (11687)
- Genomics (15914)
- Immunology (11027)
- Microbiology (26069)
- Molecular Biology (10637)
- Neuroscience (56518)
- Paleontology (417)
- Pathology (1731)
- Pharmacology and Toxicology (3003)
- Physiology (4542)
- Plant Biology (9624)
- Synthetic Biology (2685)
- Systems Biology (6975)
- Zoology (1508)